Anorexia News and Research

RSS

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).

30 Apr 2014

Oral health: The gateway to your overall health

If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.

25 Apr 2014

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression.

23 Apr 2014

Eating Recovery Center collaborates with Eating Disorder Center at San Antonio

Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).

16 Apr 2014

Brain disconnect leaves teen brain less able to judge trustworthiness

Making a snap decision usually means following your initial reaction -- going with your gut. That intuitive feeling sprouts from the limbic system, the evolutionarily older and simpler part of the brain that affects emotion, behavior and motivation.

1 Apr 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

GW SPHHS to hold public forum on prevalence and impact of eating disorders

The George Washington (GW) University School of Public Health and Health Services (SPHHS) will hold a public forum on February 25 that will address the prevalence and impact of eating disorders, especially on college campuses.

20 Feb 2014

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Study identifies patterns of brain activity associated with eating disorders

A growing body of evidence shows the impact of diet on brain function, and identifies patterns of brain activity associated with eating disorders such as binge eating and purging. The findings were presented at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

14 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

Researchers highlight presence of specific antibodies that regulate appetite in obese patients

Obesity affects more than 15% of adults in France, and its constitutive mechanisms are still not completely explained. Normally, fine control of weight and food intake is coordinated by a specialised part of the brain (the hypothalamus).

31 Oct 2013

Psychotherapy: New treatment choice for anorexia nervosa

A large-scale study has now shown that adult women with anorexia whose disorder is not too severe can be treated successfully on an out-patient basis. Even after conclusion of therapy, they continue to make significant weight gains.

22 Oct 2013

Skin cancer drug shows periocular promise

Early research suggests that patients with periocular basal cell carcinoma may benefit from treatment with a drug targeting the Hedgehog signaling pathway.

21 Oct 2013

Slow caress or stroke may play part in creating, sustaining positive sense of self

A loving touch, characterized by a slow caress or stroke - often an instinctive gesture from a mother to a child or between partners in romantic relationships - may increase the brain's ability to construct a sense of body ownership and, in turn, play a part in creating and sustaining a healthy sense of self.

9 Oct 2013

Binge eating disorder is different from anorexia nervosa and bulimia nervosa

Food addiction is not yet recognised as a mental disorder but certain obese individuals clearly display addictive-like behaviour towards food.

9 Oct 2013

Two gene mutations associated with increased risk of developing eating disorders

Eating disorders like anorexia nervosa and bulimia often run in families, but identifying specific genes that increase a person's risk for these complex disorders has proved difficult.

9 Oct 2013

Anorexia News and Research

Amgen presents extended analysis of PEAK study data at ASCO

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Oral health: The gateway to your overall health

UT Southwestern researchers identify potential new treatment for depression

Eating Recovery Center collaborates with Eating Disorder Center at San Antonio

Brain disconnect leaves teen brain less able to judge trustworthiness

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

GW SPHHS to hold public forum on prevalence and impact of eating disorders

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Study identifies patterns of brain activity associated with eating disorders

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Researchers highlight presence of specific antibodies that regulate appetite in obese patients

Psychotherapy: New treatment choice for anorexia nervosa

Skin cancer drug shows periocular promise

Slow caress or stroke may play part in creating, sustaining positive sense of self

Binge eating disorder is different from anorexia nervosa and bulimia nervosa

Two gene mutations associated with increased risk of developing eating disorders

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News